Suppr超能文献

通过对小卫星或Y染色体标记进行PCR扩增来检测白血病患者非T细胞去除性骨髓移植后的受者细胞,具有不同的预后价值。

Detection of recipient cells after non T-cell depleted bone marrow transplantation for leukemia by PCR amplification of minisatellites or of a Y chromosome marker has a different prognostic value.

作者信息

Landman-Parker J, Socie G, Petit T, Raynal B, Bourhis J H, Pico J, Brison O

机构信息

Laboratoire d'Oncologie Moléculaire, URA 1158 CNRS Institut Gustave Roussy, Villejuif, France.

出版信息

Leukemia. 1994 Nov;8(11):1989-94.

PMID:7967743
Abstract

We used polymerase chain reaction amplification of minisatellite sequences (33.6.3, MS51, YNZ22) and of a Y chromosome-specific sequence (DYZ1) to document prospectively chimerism in 23 leukemia patients grafted with non T-cell depleted marrows from HLA-identical sibling donors. Twenty-two patients had a complete hematopoietic chimerism (within the sensitivity limit of the method used: 1%) early (about 1 month) after transplantation and one had detectable residual host cells (partial chimerism). These cells were still present after 8 months, and this patient relapsed 16 months after transplantation. Two patients with early complete chimerism relapsed 16 and 17 months after transplantation. Seven patients died from toxicity or infections and 13 are in clinical remission with a follow-up of 16 to 48 months. Nine male patients grafted with the marrow from a female donor were also studied by amplification of the DYZ1 marker (0.01% sensitivity). In all nine cases, residual male nucleated cells were detected early and up to 1 year after transplantation. These results suggest that the detection of persistent residual recipient cells above a 1% level might be predictive of relapse but that the detection of such cells in a 0.01-1% range is probably unrelated to relapse and does not seem to influence the outcome of the transplantation procedure.

摘要

我们运用聚合酶链反应扩增小卫星序列(33.6.3、MS51、YNZ22)以及Y染色体特异性序列(DYZ1),对23例接受来自 HLA 相同同胞供者的非 T 细胞去除骨髓移植的白血病患者进行前瞻性嵌合体研究。22例患者在移植后早期(约1个月)出现完全造血嵌合体(在所使用方法的灵敏度范围内:1%),1例患者检测到残留宿主细胞(部分嵌合体)。这些细胞在8个月后仍存在,该患者在移植后16个月复发。2例早期完全嵌合体患者在移植后16个月和17个月复发。7例患者死于毒性反应或感染,13例处于临床缓解期,随访时间为16至48个月。9例接受女性供者骨髓移植的男性患者也通过扩增DYZ1标记物(灵敏度为0.01%)进行了研究。在所有9例病例中,移植后早期及长达1年时均检测到残留的男性有核细胞。这些结果表明,检测到持续残留的受体细胞水平高于1%可能预示复发,但检测到处于0.01 - 1%范围内的此类细胞可能与复发无关,且似乎不影响移植手术的结果。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验